Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 35: 1631-1637, 1989;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by O'Connor, D. T.
Right arrow Articles by Hslao, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O'Connor, D. T.
Right arrow Articles by Hslao, R. J.

Clinical Chemistry, Vol 35, 1631-1637, Copyright © 1989 by American Association for Clinical Chemistry

Rapid radioimmunoassay of circulating chromogranin A: in vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effects of organ failure

DT O'Connor, MR Pandlan, E Carlton, JH Cervenka and RJ Hslao
Department of Medicine, University of California, San Diego.

Chromogranin A is a useful probe of neuroendocrine neoplasia in humans. Here we optimize a rapid, sensitive radioimmunoassay modification for detecting chromogranin A in humans and other species. The site of chromogranin A circulation is the acellular plasma; platelets contain no chromogranin A immunoreactivity. The immunoreactivity in plasma is stable to repeated freezing and thawing, prolonged incubation at 37 degrees C, and lyophilization. Venipuncture alone resulted in modest (+ 12%, P less than 0.03) increase in chromogranin A in plasma. Several classic neuroendocrine neoplasia-pheochromocytoma, carcinoid tumor, neuroblastoma, and (vasoactive intestinal polypeptide)oma-produce markedly increased chromogranin A in plasma. By contrast, subjects with malignant melanoma, renal cell carcinoma, and thymoma all had normal values for chromogranin A. Hypersecretion of human choriogonadotropin beta subunit from both malignant (choriocarcinoma) and normal (placenta) syncytiotrophoblast cells was unaccompanied by an increase in chromogranin A, a dissociation compatible with the lack of granular storage and release of syncytiotrophoblastic peptide hormones. Both hepatic and renal failure resulted in increased chromogranin A in plasma, with renal failure leading to concentrations otherwise seen only in neuroendocrine neoplasia. These observations refine the diagnostic specificity of chromogranin A in plasma.


The following articles in journals at HighWire Press have cited this article:


Home page
 J. Clin. Endocrinol. Metab.Home page
K. A. S. Al-Shoumer and B. A. Vasanthy
Serum Chromogranin A Concentration in Hyperthyroidism before and after Medical Treatment
J. Clin. Endocrinol. Metab., July 1, 2009; 94(7): 2321 - 2324.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
A. M. Jansson, H. Rosjo, T. Omland, T. Karlsson, M. Hartford, A. Flyvbjerg, and K. Caidahl
Prognostic value of circulating chromogranin A levels in acute coronary syndromes
Eur. Heart J., January 1, 2009; 30(1): 25 - 32.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
M. Pieroni, A. Corti, B. Tota, F. Curnis, T. Angelone, B. Colombo, M. C. Cerra, F. Bellocci, F. Crea, and A. Maseri
Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function
Eur. Heart J., May 1, 2007; 28(9): 1117 - 1127.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
S. Sorhaug, A. Langhammer, H. L. Waldum, K. Hveem, and S. Steinshamn
Increased serum levels of chromogranin A in male smokers with airway obstruction
Eur. Respir. J., September 1, 2006; 28(3): 542 - 548.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
L. Taupenot, K. L. Harper, and D. T. O'Connor
The Chromogranin-Secretogranin Family
N. Engl. J. Med., March 20, 2003; 348(12): 1134 - 1149.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
C. Ceconi, R. Ferrari, T. Bachetti, C. Opasich, M. Volterrani, B. Colombo, G. Parrinello, and A. Corti
Chromogranin A in heart failure. A novel neurohumoral factor and a predictor for mortality
Eur. Heart J., June 2, 2002; 23(12): 967 - 974.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. d'Herbomez, V. Gouze, D. Huglo, M. Nocaudie, F. Pattou, C. Proye, J.-L. Wemeau, and X. Marchandise
Chromogranin A Assay and 131I-MIBG Scintigraphy for Diagnosis and Follow-Up of Pheochromocytoma
J. Nucl. Med., July 1, 2001; 42(7): 993 - 997.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
F. Rao, H. R. Keiser, and D. T. O'Connor
Malignant Pheochromocytoma : Chromaffin Granule Transmitters and Response to Treatment
Hypertension, December 1, 2000; 36(6): 1045 - 1052.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. Ischia, R. W. Gasser, R. Fischer-Colbrie, U. Eder, A. Pagani, L. X. Cubeddu, P. Lovisetti-Scamihorn, G. Finkenstedt, A. Laslop, and H. Winkler
Levels and Molecular Properties of Secretoneurin-Immunoreactivity in the Serum and Urine of Control and Neuroendocrine Tumor Patients
J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 355 - 360.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. Granberg, M. Stridsberg, R. Seensalu, B. Eriksson, G. Lundqvist, K. Öberg, and B. Skogseid
Plasma Chromogranin A in Patients with Multiple Endocrine Neoplasia Type 1
J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2712 - 2717.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
S. K. Mahata, M. Mahata, R. J. Parmer, and D. T. O'Connor
Desensitization of Catecholamine Release. THE NOVEL CATECHOLAMINE RELEASE-INHIBITORY PEPTIDE CATESTATIN (CHROMOGRANIN A344-364) ACTS AT THE RECEPTOR TO PREVENT NICOTINIC CHOLINERGIC TOLERANCE
J. Biol. Chem., January 29, 1999; 274(5): 2920 - 2928.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
F. R. E. Nobels, D. J. Kwekkeboom, W. Coopmans, C. H. H. Schoenmakers, J. Lindemans, W. W. De Herder, E. P. Krenning, R. Bouillon, and S. W. J. Lamberts
Chromogranin A as Serum Marker for Neuroendocrine Neoplasia: Comparison with Neuron-Specific Enolase and the {alpha}-Subunit of Glycoprotein Hormones
J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2622 - 2628.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
D. Ely, A. Caplea, G. Dunphy, H. Daneshvar, M. Turner, A. Milsted, and M. Takiyyuddin
Spontaneously Hypertensive Rat Y Chromosome Increases Indexes of Sympathetic Nervous System Activity
Hypertension, February 1, 1997; 29(2): 613 - 618.
[Abstract] [Full Text]

Home page
 HypertensionHome page
M. A. Takiyyuddin, R. J. Parmer, M. T. Kailasam, J. H. Cervenka, B. Kennedy, M. G. Ziegler, M.-C. Lin, J. Li, C. E. Grim, F. A. Wright, et al.
Chromogranin A in Human Hypertension : Influence of Heredity
Hypertension, July 1, 1995; 26(1): 213 - 220.
[Abstract] [Full Text]

Home page
 NEJMHome page
H. Neumann, D. P. Berger, G. Sigmund, U. Blum, D. Schmidt, R. J. Parmer, B. Volk, and G. Kirste
Pheochromocytomas, Multiple Endocrine Neoplasia Type 2, and von Hippel-Lindau Disease
N. Engl. J. Med., November 18, 1993; 329(21): 1531 - 1538.
[Abstract] [Full Text]

Home page
 Arch SurgHome page
B. E. Stabile, T. J. Howard, E. Passaro Jr, and D. T. O'Connor
Source of Plasma Chromogranin A Elevation in Gastrinoma Patients
Arch Surg, April 1, 1990; 125(4): 451 - 453.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1989 by the American Association for Clinical Chemistry.